Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing. No statistically significant reductions in catestatin concentrations were identified in the placebo group,” a recent article reads. “Given the growing demand for alternative anti-hypertensive treatments and therapies, Lexaria recognizes an opportunity and seeks to fill it. These latest results from its ambitious HYPER-H21-4 study inch the company closer to achieving that goal, ultimately becoming a leader and tapping into a pharmaceutical market that is set to be valued at $34 billion by 2030. Lexaria’s management is optimistic that DehydraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment.”

To view the full article, visit https://cnw.fm/G4QpC

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Bipartisan Legislators File Bill Allowing Those with Drug Convictions Access to Hemp Industry

Bipartisan congressional legislators have filed a new measure to end the “discriminatory” federal rule that prevents people with prior felonies for drug offenses from owning or operating legal hemp businesses. The “Free to Grow Act,” sponsored by Representatives Chellie Pingree (D-ME), David Trone (D-MD), Nancy Mace (R-SC) and Dave Joyce (R-OH), focuses only on the section of the 2018 Farm Bill that dealt with prior convictions and federal legalized hemp.

Pingree stated that in spite of legalization, the industry’s expansion is being hampered by bureaucracy, regulatory uncertainty and discriminatory policy. Congress is expected to approve a new farm bill version this year. The new legislation would remove provisions from the farm bill that currently prohibit individuals convicted of a felony drug offense within the previous 10 years from legally holding certain positions within a licensed hemp business.

In 2019, the USDA made it clear that only “key participants” — chief executives with a direct financial stake in the company or other top executives — would be subject to the ban. As a result, employees such as maintenance workers are exempt from the rule, which is consistent with the strict reading that advocates pushed for. The lawmakers are now attempting to completely remove the prohibitory language.

A majority of advocacy organizations, including DREAM.Org, Americans for Prosperity, Drug Policy Alliance, Due Process Institute, U.S. Hemp Roundtable and R St Institute, are supporting the proposed reform.

Pingree has been on the forefront of advocating for changes to the hemp sections of the bill, filing separate measures in past sessions that incorporated proposed revisions supported by a majority of the industry players. Those revisions include items such as increasing the THC levels for legal hemp and eliminating a clause that hemp should only be tested by DEA-certified laboratories.

Regarding the latter, the USDA did declare at the end of 2022 that it was temporarily postponing enforcement of the requirement because such facilities lacked “adequate” capacity. The rule did not go into effect on Jan. 1, 2023, and will not go into effect until at least Dec. 31, 2023.

In January, the USDA made the announcement that it would begin publishing a weekly newsletter with “unbiased, timely and accurate data” about the hemp industry. In an annual effort to better understand how the market has changed, the department began sending out surveys to hemp farmers across the nation shortly after that development.

The Congressional Research Service also published a report last year outlining a number of ways stakeholders hoped to see federal hemp laws changed to better support the sector through the upcoming farm bill.

As more people are freed from the unwarranted restrictions barring them from participating in the hemp industry, it will create downstream opportunities for enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) engaged in supplying equipment that can be used to grow different plants indoors, such as cannabis.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DOJ Appeals Federal Ruling on Gun Rights for Marijuana Users

The U.S. Department of Justice is appealing a recent ruling by Federal Judge Patrick Wyrick that deemed it unconstitutional to prevent people who use state-legal marijuana from using guns. The Justice Department revealed in a filing to the Western District of Oklahoma U.S. District Court that it would appeal the ruling at the U.S. Court of Appeals for the Tenth Circuit.

The appeal announcement by the U.S. government comes just a month after Wyrick’s landmark ruling.

Although the two-page filing doesn’t elaborate on the arguments behind the ban, U.S. Attorney Robert Troester and Assistant U.S. Attorney David McCray will flesh the arguments out in future filings at the appeals court.

In early February, Wyrick ruled that the statute prohibiting marijuana users from possessing firearms was in direct violation of the second amendment of the Constitution. Wyrick dismissed charges against an Oklahoma resident who had been arrested and charged after police found marijuana and a handgun in his vehicle after a traffic stop. He based his ruling on an interpretation of a prior Supreme Court ruling where the justices created a precedent of policies that imposed restrictions on Americans’ gun rights.

According to this ruling, any restrictions to the second amendment must remain consistent with the legislation’s original ratification in 1791.

Wyrick noted that cannabis use does not automatically make one “unvirtuous and dangerous” as the drug’s “mere use” does not involve threatening, forceful or violent conduct. He said that the historical analogues the Justice Department was using to justify gun rights restrictions for marijuana users “missed the mark” and did not provide enough basis for a historical analogue.

A few months before that, then-Florida Commissioner of Agriculture Nikki Fried unsuccessfully tried to challenge a law that prevented medical marijuana patients in the state from purchasing and owning firearms. She and her co-plaintiffs went on to file an appeal at the U.S. Court of Appeals for the Eleventh Circuit on the basis that preventing medical marijuana patients from exercising their second amendment rights is unconstitutional.

In a May 2022 op-ed, Fried said that it was time for the federal government to catch up on marijuana, arguing that current federal cannabis laws are discriminatory and have a “widespread, negative impact on communities of color.” She said that the discrepancies in state and federal law are preventing thousands of people from gaining employment as well as access to capital, housing and education.

The gun rights under question affect individuals who use state-legal marijuana products, but those who use FDA-approved products, such as those that India Globalization Capital Inc. (NYSE American: IGC) hopes to successfully take through the clinical development process and attain FDA approval, can own firearms legally.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Cannabis Advocates Pin Hopes on Delaware, Hawaii After Ballot Defeat in Oklahoma

Oklahoma voters recently rejected a measure that would have legalized recreational cannabis in the state and expanded access to adults aged 21 and older. With this decision, Oklahoma joined a group of conservative states that have recently rejected measures to legalize adult-use cannabis, including North Dakota, Arkansas and South Dakota.

The recreational marijuana measure’s failure to pass in Oklahoma was a blow to advocates, who were hoping that changing attitudes among younger voters coupled with laissez-faire economic attitudes would swing the vote in favor of cannabis. Even though 10% of Oklahomans currently hold a medical cannabis card, 63% of voters rejected the measure while only 38% were in favor of legalizing recreational cannabis.

In the wake of their recent setback in Oklahoma, legalization advocates are now turning their attention to Delaware and Hawaii where the prospects of legalization are much greater. Both states are currently host to bills that would legalize recreational cannabis for adults aged 21 and older.

The measure in Hawaii has support from Governor Josh Green while the Delaware measure has a veto-proof majority among state lawmakers. Green noted during his campaign trail that he would sign a recreational cannabis bill into law if he was elected governor and the legislature sent him an adult-use bill.

In Delaware, an adult-use bill was vetoed by Governor John Carney and is now headed to the senate for a vote that could override Carney’s veto.

Even though the prospects of legalizing cannabis in larger states such as Pennsylvania and Ohio are still uncertain, Delaware and Hawaii seem to be on track to legalize cannabis. Democrats have control over the house and senate in both states, and both governors are from the Democratic party, meaning they can effectively pass cannabis legislation with little effective pushback from the GOP.

Minnesota, which also has a legalization bill going through the legislature, has a similar Democratic trifecta.

However, advocates concede that some conservative Democratic senators may have to be convinced to vote in favor of legalizing adult-use cannabis

While successfully passing cannabis legalization measures in small Democratic states such as Hawaii and Delaware would certainly be a solid step in the right direction, it may not have a major domino effect on the rest of the country’s adult-use industry. Succeeding in a conservative state such as Oklahoma would have had a much wider ripple effect and could have even caused lawmakers in other conservative states to rethink their cannabis policies. Furthermore, cannabis reform in conservative states could even pressure lawmakers at the federal level to consider federal cannabis reform.

Companies such as Advanced Container Technologies Inc. (OTC: ACTX), which specialize in meeting the needs of entities within the cannabis industry, will be keeping an eye on the progress of the cannabis legalization movement since it could open more opportunities for them.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Pharmacologist Highlights Untapped Potential in Several Cannabinoids

Medical cannabis dispensaries have a growing selection of products for anxiety, pain, sex and other conditions, with many available strains having magical and evocative names such as Bubba Kush, Blue Dream and Chocolope. But what exactly does this mean? Do the various strains’ medical properties differ from one another? Or are the creative names merely marketing ploys?

Cannabis is not just a source of cannabinoids, as several studies have shown. The plants is an especially abundant source of therapeutic substances that humans have not yet fully explored. But to fully utilize the plant’s potential, society must move past its prejudices against marijuana and consider what the evidence unambiguously demonstrates about its therapeutic value.

The FDA has already taken steps in this direction by approving prescription medications made from marijuana, such as cannabidiol (CBD), dronabinol, nabiximols and nabilone. Nabilone and dronabinol are used to treat nausea, while CBD and nabiximols, which contain THC, the psychoactive ingredient in marijuana, are used for multiple sclerosis.

Cannabis contains at least 27 terpenes and 85 cannabinoids. Terpenes refer to fragrant oils produced by numerous flowers and herbs as well as possibly active, drug-like substances.

THC is the most common cannabinoid. It comes from THC acid, which contains up to 25% of the plant’s dry weight. Tetrahydrocannabivarin, which comes from tetrahydrocannabivarinic acid, also leads to a high when ingested or smoked in baked products. However, some cannabinoids, like CBD, do not cause a high.

Additionally, cannabis contains a number of monoterpenoids, which are small, aromatic molecules with a wide range of functions, including the reduction of pain and anxiety. The most prevalent monoterpenoid is myrcene, which can be used to ease muscle tension.

The market is flooded with numerous cannabis varieties, all claiming to treat a variety of conditions, over which the FDA has no control because it does not legally recognize marijuana. So, how can you be sure that the strain you select is legal and likely to have health benefits?

Every strain ought to have an analysis certificate that details the amounts of each active ingredient in the product you purchase. A majority of states have a cannabis control department that validates these certificates. Many certificates, however, fail to list the monoterpenoids content level since it tends to evaporate from the plant matter. Ask for evidence if you’re looking for a strain with a lot of linalool or myrcene.

It’s also important to remember that, although cannabis can treat a range of ailments, it can also exacerbate other disorders and have unpleasant side effects.For example, the legalization of recreational cannabis has resulted in the rise of cannabis hyperemesis syndrome, a condition in which people experience uncontrollable vomiting after regularly consuming marijuana.

Additionally, high-THC marijuana strains such as Fat Banana and Royal Gorilla can make some people anxious and even go into psychosis.

The scientific community needs to conduct more research to help determine the proper, secure use of cannabis. However, the FDA’s refusal to acknowledge medical cannabis uses makes marijuana research funding a challenge. Perhaps the industry should think about supporting marijuana-related scientific research. Conflicts of interest, however, might become an issue, as we have seen with studies funded by pharmaceutical companies.

Startups such as India Globalization Capital Inc. (NYSE American: IGC) are looking to leverage the potential of many of these cannabinoids in order to develop formulations that get FDA-approved for use in the medical system.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — More Companies Stop Preemployment Marijuana Tests as Legalization Spreads

Employers are opting to do away with drug screening tests amid a major labor shortage that has caused a deficit of around 3.5 million workers in the workforce. The transportation industry has been especially affected by the labor shortage, with employers in the sector struggling to find enough warehouse personnel, public transit workers, couriers and truck drivers. The food and hospitality industries as well as health care and retail trade have also been grappling with worker shortages for a while.

Some companies are now choosing to stop marijuana screening tests for new potential employees as they can reduce the worker pool by a wide margin.

With nearly one-half of Americans living in states that allow recreational cannabis sales and even more residing in states with medical marijuana markets, plenty of Americans are using cannabis either recreationally or for medical purposes. But since cannabis is still illegal at the federal level, employers are allowed to screen employees or potential workers for cannabis and either dismiss them or decline to hire them if they fail a drug test.

Drug test company Quest Diagnostics reports that 4.6% of the tests it carried out in 2021 were positive for marijuana, the highest in 20 years. This was a nearly 50% increase from the 2.7% of drug tests conducted in 2020 that tested positive for marijuana. However, the number of firms screening for cannabis has reduced by 10% in states with legal cannabis markets.

It seems more companies are choosing to eliminate pre-employment drug tests in an effort to fill up their ranks. Companies are desperate to keep remaining workers and hire new ones in a labor landscape that has been termed the Great Resignation due to the voluntary resignation of 47.4 million employees in 2021.

Amazon announced that it would stop testing for cannabis in June 2021, and a 2021 survey from staffing company Manpower Group revealed that at least 9% of 45,000 companies were thinking of eliminating pre-employment drug screenings.

According to employment attorney Bernard Tisdale, companies that would like to stop testing for marijuana first have to go through a complex checklist such as whether it is a safety-sensitive position or a federal contractor. Tisdale says that some of his clients have stopped testing for cannabis in low-skilled job applications as this made it harder to fill the positions. He added that employers who don’t test during the hiring process still have the right to screen for cannabis if an employee is showing clear signs of impairment at work.

As drug-testing rules are relaxed by employers, more people could become comfortable consuming marijuana products, and that could indirectly boost manufacturing activity in several niches, such as the production of indoor cultivation equipment by enterprises such as Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — California Kickstarts $20M Grant Initiative to Boost Marijuana Retail Sales

California’s Cannabis Control Department (DCC) launched a $20 million grant program to help local governments increase consumer access to legal marijuana products. The Local Jurisdiction Retail Access Grant, which is being hailed as the first program of its kind in the country, aims to give local governments the tools they need to increase access to cannabis products in marginalized areas.

According to the department, the grant program will make use of current licensing and permitting procedures to create and implement marijuana retail licensing programs in regions of California where cannabis use is prevalent, but consumers have little to no access to legal retail.

During the news release, DCC director Nicole Elliott stated that expanding access to the state’s retail marijuana market was a critical step in ensuring consumer safety and promoting a healthy market. The lack of retail access to cannabis has long been a major issue for the state, even causing annual sales to fall in 2022 for the first time since recreational marijuana was legalized in 2018.

Most areas of California are considered marijuana deserts since a majority of the counties and cities forbid retail sales, which severely limits the market’s potential growth. One such area is Orange County, which has no cannabis retail. The county, despite being the third largest in the state, only permits cannabis sales in four cities: Costa Mesa, Stanton, La Hambra and Santa Ana.

According to the DCC, California has about 33 counties that do not permit cannabis licenses, with nine of them having significant marijuana consumption. These counties, as well as the cities within them, will be given priority review in the event that they submit a grant application and set up a permitting program.

The department will start accepting applications for grants from March 10, 2023. There will be two phases to the distribution of grant funds, with the deadline for phase I funding being April 28, 2023. DCC also released grant guidelines, which described the requirements for applications.

Local governments that either don’t have a cannabis retail program or have plans to adopt one are qualified for grant funding. The grants can be used to fund environmental reviews, licensee and equity applicant assistance, permitted expenses and personnel costs. The program will first distribute grants totaling up to $10 million by June 20, 2023. Then the remaining $10 million will be made available to awardees after June 30 once the DCC begins issuing licenses, which could take as long as 2024 or even longer.

However, no such grant programs exist for companies such as India Globalization Capital Inc. (NYSE American: IGC) seeking to commercialize THC-based treatments for indications, including chronic pain and other clinical conditions.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

  • Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
  • The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
  • The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
  • With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.

The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in the diabetes animal model, the company is encouraged by the positive findings. Moreover, it is confident that the results indicate many prospective benefits worthy of further investigation together, possibly with other drugs that help to control glucose levels directly.

Lexaria set out to explore the therapeutic utility of DehydraTECH-CBD against diabetes in November 2022, on the heels of the success of its clinical studies on hypertension. The company’s management was optimistic that the results from the hypertension study would be replicated in the diabetes study, given that hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes.

The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore DehydraTECH’s application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more. With DehydraTECH having proven to increase the effectiveness and the way active pharmaceutical ingredients enter the bloodstream, Lexaria is exploring its full potential for improving consumer products. Its efforts have seen the company awarded 28 patents, with more patents pending worldwide.

Diabetes is the 7th largest cause of death in the United States and accounts for an estimated value of $26.7 billion in the global diabetes devices market. Lexaria’s management is hopeful that its current efforts and studies will inch the company closer to taking advantage of this industry’s market potential. In 2021, the global diabetes drug market was estimated at $63.1 billion and is projected to hit $80.65 billion by 2027. With the company’s unique technology, a growing list of patents, and unique market positioning, Lexaria is set to capitalize on this growth and become a leader in the drug delivery technology space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Pittcon Research Could Help Regulate Levels of Synthetic and Natural Cannabinoids

Psychedelics and cannabis are probably two of the most common psychoactive drugs, or substances that change physiological and psychological functions. These drugs can affect daily life in both negative and positive ways when used.

For instance, when administered correctly, cannabis may be used as a therapeutic option for a range of neurological conditions such as Alzheimer’s, Parkinson’s and brain cancer. Contrarily, recreational cannabis has been linked to issues with mood, cognition and other symptoms.

Cannabinoids, which are naturally occurring substances in the marijuana plant, are what cause the drug’s psychological and physical side effects. The most popular cannabinoids are tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabigerol (CBG). While THC gives cannabis its “high,” CBD and CBG affect pain perception, appetite and memory and are primarily used to treat diseases such as multiple sclerosis and reduce inflammation and anxiety.

The increased legalization of cannabis has led to the emergence of many products that are now available for both recreational and medical use. But to keep up with the rapidly evolving cannabinoid market, there is now a need to diversify policies in public health.

Developing novel methods for analyzing psychoactive substances using techniques such as liquid chromatography, gas chromatography and mass spectrometry can assist in addressing some of the cannabis therapeutic and regulatory issues.

On the flip side, synthesized cannabinoids are artificial chemicals that mimic the effects of marijuana but are more hazardous as a food additive than natural cannabinoids because they are less well-known, less predictable and have unpredictable effects. Sometimes, producers of marijuana-based products add synthetic cannabinoids to their products because they are easier, quicker and cheaper to produce. Consumers are at risk from this practice, however, as it increases the likelihood of product contamination and lowers quality. Synthetic cannabinoids can also have negative side effects and are difficult to regulate.

The development of innovative drugs will play a significant role in the rapid, efficient and accurate identification and quantification of both natural and synthetic cannabinoids, which will be a major step toward developing regulatory policy and implementing health interventions. As a result, more research on cannabinoids’ effects and biochemistry is required.

Pittcon is at the leading edge of this research, pushing the boundaries of study into psychoactive substances. Researchers are expected to present a number of studies that have examined marijuana and other psychoactive substances at Pittcon this year. The presentations will be crucial to advancing innovation in the cannabis and psychedelics industries, assisting in the better formulation of strategies to curtail the inappropriate use of these substances and develop potential medical treatments.

Industry experts and scientists will highlight the technologies and methodologies used to identify and measure levels of cannabinoids as well as evaluate the quality of cannabinoid products on legal and illegal markets.

As more resources are directed towards understanding both natural and synthetic cannabinoids, innovative products, such as indoor “microgardens” from manufacturers like Advanced Container Technologies Inc. (OTC: ACTX) are also becoming available on the market across the country.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Missouri Expunges at Least 7,500 Cannabis Convictions

Missouri has expunged the records of more than 7,500 people who had prior cannabis-related convictions. The state legalized recreational cannabis last year after voters approved an amendment to allow adults aged 21 and older to purchase, possess and consume cannabis.

On top of legalizing recreational cannabis, the constitutional amendment also allowed individuals convicted of nonviolent cannabis offenses to petition for release from prison, parole and expungements of their records.

Riverfront Times reports that the measure kicked off a process of expunging cannabis offenses from criminal records. Misdemeanors have made up the majority of the cases that have been expunged so far, the report says, with courts expunging 6,121 nonviolent marijuana-related misdemeanors and more than 1,200 felony convictions.

Misdemeanors that involved driving under the influence of cannabis or selling cannabis to minors did not qualify for the expungement. Individuals who are currently incarcerated for qualified cannabis offenses qualify for the expungement and at least one person has already been released.

The expungement process is going faster than expected, said secretary of the National Organization for the Reform of Marijuana Laws (NORML) Dan Viets. Viets coauthored the state’s recreational and medical cannabis regulations. Overall, it seems like Missouri is fast-tracking its efforts to implement recent cannabis laws.

Adult-use cannabis sales began earlier than expected and just a month after the state Department of Health and Senior Services (DHSS) said that it was nearly done drafting rules for the new recreational cannabis program. The department said in January that once the new rules were effective, it would begin approving requests from licensed medical cannabis dispensaries to convert their licenses and allow them to sell both medical and recreational cannabis.

The DHSS also said that it would begin taking applications to allow people aged 21 years and older to grow cannabis at home for personal use in enclosed and locked facilities.

Amendment 3 set deadlines for courts to complete expungements for people with nonviolent marijuana-related offenses. The deadline for people who are currently serving time for cannabis-related misdemeanors was March 8, 2023, while the deadline for expunging other crimes is around three and a half months away, the Times said. Circuit courts have until June 8, 2023, to facilitate the expungement of all misdemeanor cannabis offenses for individuals who aren’t under the Department of Correction’s supervision.

Furthermore, the state’s circuit courts have up to December 8, 2023, to expunge the records of people who had already served time for federal cannabis offenses that are now considered legal activities.

Meanwhile, significant strides forward are being made by companies such as India Globalization Capital Inc. (NYSE American: IGC), which specialize in developing medicinal formulations from various cannabinoids, such as THC.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.